Searched for
IGI EBITDA MARGIN
IGI shares hit 10% upper circuit as Q2 profit jumps 43%, revenue rises 31% YoYInternational Gemological Institute shares hit the 10% upper circuit after Q2 FY27 revenue rose 31% and profit surged 43% year on year. Gro...- IGI India Q2 PAT jumps 63% YoY; margins, growth remain strongIGI India reported robust Q2 FY25 results, with revenue up 16% and PAT surging 63% YoY. EBITDA rose 37%, driven by strong momentum across a...
- Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&PS&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVi...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Reduce Glenmark Pharmaceuticals, target price Rs 1,265: ICICI SecuritiesICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...
- Glenmark Pharma shares in focus as company swings back to profit in Q3Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previou...
- Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35%Glenmark Pharmaceuticals Q3 Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY...
- IGI to use IPO proceeds of India entity to make acquisitions: IGI managementIGI, a leading gemstone and diamond certification body, is pursuing an IPO in India to consolidate its global operations and capitalize on ...
- IGI offers long-term play for investors keen on niche bizThe company's revenues grew at a CAGR of 32.3% from ₹365 crore in FY22 to ₹638 crore in FY24. Net profit rose at a CAGR of 37.6% to ₹325 cr...
Load More
